Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.58 +0.11 (+0.63%)

Official Closing Price Updated: 7:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

April 26, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

April 25, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

April 24, 2023

From Bausch + Lomb Corporation

Via Business Wire

Analyst Expectations for Bausch & Lomb's Future ↗

March 23, 2023

Via Benzinga

The Latest Analyst Ratings for Bausch & Lomb ↗

February 24, 2023

Via Benzinga

7 Analysts Have This to Say About Bausch & Lomb ↗

December 21, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Bausch & Lomb ↗

November 23, 2022

Via Benzinga

Expert Ratings for Bausch & Lomb ↗

November 03, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

April 20, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

April 18, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

April 17, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

April 13, 2023

From Bausch + Lomb

Via Business Wire

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

April 12, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

March 22, 2023

From Bausch + Lomb Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

February 22, 2023

From Bausch + Lomb Corporation

Via Business Wire

Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday ↗

February 15, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

February 15, 2023

From Bausch + Lomb Corporation

Via Business Wire

New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

February 07, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

February 01, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

January 23, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Acquires AcuFocus, Inc.

January 17, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

January 09, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

January 09, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

January 04, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

January 03, 2023

From Bausch + Lomb Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗

December 21, 2022

Via Benzinga

Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13 ↗

December 13, 2022

Benzinga Sam Bankman-Fried Arrested In The Bahamas

Via Benzinga

Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits ↗

December 13, 2022

More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO).

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.